Robert LeBoyer

Stock Analyst at Noble Capital Markets

(1.90)
# 3,231
Out of 5,032 analysts
18
Total ratings
43.75%
Success rate
4.12%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $18.62
Upside: +275.94%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $7.48
Upside: +73.80%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6$10
Current: $0.55
Upside: +1,709.95%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $4.71
Upside: +1,173.89%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $13.63
Upside: +340.21%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.44
Upside: +190.70%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.28
Upside: +993.75%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.65
Upside: +384.85%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.62
Upside: +19,254.84%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $15.65
Upside: -
Initiates: Buy
Price Target: $12
Current: $8.98
Upside: +33.63%
Initiates: Buy
Price Target: $9,900,000
Current: $9.20
Upside: +107,608,595.65%
Downgrades: Neutral
Price Target: n/a
Current: $20.23
Upside: -
Initiates: Buy
Price Target: $15
Current: $3.05
Upside: +391.56%